The effectiveness and value of ensifentrine for the treatment of chronic obstructive pulmonary disease.
作者信息
Wright Abigail C, Lin Grace A, Whittington Melanie D, McKenna Avery, Raymond Finn, Rind David M, Agboola Foluso
机构信息
Institute for Clinical and Economic Review, Boston, MA.
Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, MA.
出版信息
J Manag Care Spec Pharm. 2024 Nov;30(11):1338-1342. doi: 10.18553/jmcp.2024.30.11.1338.
Abstract
摘要
相似文献
1
The effectiveness and value of ensifentrine for the treatment of chronic obstructive pulmonary disease.恩昔芬净治疗慢性阻塞性肺疾病的有效性和价值。
J Manag Care Spec Pharm. 2024 Nov;30(11):1338-1342. doi: 10.18553/jmcp.2024.30.11.1338.
2
What role will ensifentrine play in the future treatment of chronic obstructive pulmonary disease patients? Implications from recent clinical trials.依司特伦在慢性阻塞性肺疾病患者治疗中的作用如何？来自近期临床试验的启示。
Immunotherapy. 2023 Dec;15(18):1511-1519. doi: 10.2217/imt-2023-0136. Epub 2023 Oct 2.
3
Effect of ensifentrine on dyspnea in patients with moderate-to-severe chronic obstructive pulmonary disease: pooled analysis of the ENHANCE trials.恩司氟烷对中重度慢性阻塞性肺疾病患者呼吸困难的影响：ENHANCE 试验的汇总分析。
Expert Rev Respir Med. 2024 Aug;18(8):645-654. doi: 10.1080/17476348.2024.2389960. Epub 2024 Aug 8.
4
Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials).依诺司特，一种新型磷酸二酯酶 3 和 4 抑制剂，用于治疗慢性阻塞性肺疾病：随机、双盲、安慰剂对照、多中心 III 期临床试验（ENHANCE 试验）。
Am J Respir Crit Care Med. 2023 Aug 15;208(4):406-416. doi: 10.1164/rccm.202306-0944OC.
5
Symptom Improvement Following Treatment with the Inhaled Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine in Patients with Moderate to Severe COPD - A Detailed Analysis.吸入性双磷酸二酯酶3和4抑制剂恩昔芬净治疗中重度慢性阻塞性肺疾病患者后的症状改善——详细分析
Int J Chron Obstruct Pulmon Dis. 2020 Sep 16;15:2199-2206. doi: 10.2147/COPD.S263025. eCollection 2020.
6
A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD.一项评估吸入型双重磷酸二酯酶 3 和 4 抑制剂恩西司特林治疗 COPD 的剂量范围研究。
Respir Res. 2020 Feb 10;21(1):47. doi: 10.1186/s12931-020-1307-4.
7
Ensifentrine as a Novel, Inhaled Treatment for Patients with COPD.恩塞福林作为一种新型吸入疗法用于 COPD 患者的治疗。
Int J Chron Obstruct Pulmon Dis. 2023 Jul 28;18:1611-1622. doi: 10.2147/COPD.S413436. eCollection 2023.
8
Effect of Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine on Exacerbation Rate and Risk in Patients With Moderate to Severe COPD.双重磷酸二酯酶3和4抑制剂恩昔芬净对中度至重度慢性阻塞性肺疾病患者急性加重率及风险的影响
Chest. 2025 Feb;167(2):425-435. doi: 10.1016/j.chest.2024.07.168. Epub 2024 Aug 27.
9
Ensifentrine (RPL554): an inhaled 'bifunctional' dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease.恩西芬特林（RPL554）：一种用于治疗哮喘和慢性阻塞性肺疾病的吸入型“双功能”双重磷酸二酯酶3/4抑制剂。
Pharm Pat Anal. 2018 Nov;7(6):249-257. doi: 10.4155/ppa-2018-0030. Epub 2019 Jan 18.
10
A Dose-Ranging Study of the Novel Inhaled Dual PDE 3 and 4 Inhibitor Ensifentrine in Patients with COPD Receiving Maintenance Tiotropium Therapy.一项新型吸入性双重 PDE3 和 4 抑制剂恩西特林在接受噻托溴铵维持治疗的 COPD 患者中的剂量范围研究。
Int J Chron Obstruct Pulmon Dis. 2021 Apr 22;16:1137-1148. doi: 10.2147/COPD.S307160. eCollection 2021.
引用本文的文献
1
Advancing the conversation: 30 years of scholarship in managed care pharmacy.推动对话：管理式医疗药学30年学术研究
J Manag Care Spec Pharm. 2025 Jul;31(7):617-626. doi: 10.18553/jmcp.2025.31.7.617.
本文引用的文献
1
Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials).依诺司特，一种新型磷酸二酯酶 3 和 4 抑制剂，用于治疗慢性阻塞性肺疾病：随机、双盲、安慰剂对照、多中心 III 期临床试验（ENHANCE 试验）。
Am J Respir Crit Care Med. 2023 Aug 15;208(4):406-416. doi: 10.1164/rccm.202306-0944OC.
2
Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary.慢性阻塞性肺疾病全球倡议组织2023年报告：《慢性阻塞性肺疾病全球倡议》执行摘要
Am J Respir Crit Care Med. 2023 Apr 1;207(7):819-837. doi: 10.1164/rccm.202301-0106PP.
3
Mortality in the United States, 2021.2021年美国的死亡率
NCHS Data Brief. 2022 Dec(456):1-8.
4
Interpreting Evaluating Respiratory Symptoms in COPD Diary Scores in Clinical Trials: Terminology, Methods, and Recommendations.解读慢性阻塞性肺疾病临床试验中日记评分里的呼吸症状评估：术语、方法及建议
Chronic Obstr Pulm Dis. 2022 Oct 26;9(4):576-590. doi: 10.15326/jcopdf.2022.0307.
5
Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission.迈向消除慢性阻塞性肺疾病：柳叶刀委员会报告。
Lancet. 2022 Sep 17;400(10356):921-972. doi: 10.1016/S0140-6736(22)01273-9. Epub 2022 Sep 5.
6
Triple Therapy versus Dual or Monotherapy with Long-Acting Bronchodilators for Chronic Obstructive Pulmonary Disease. A Systematic Review and Meta-analysis.三联疗法与长效支气管扩张剂双联或单药治疗慢性阻塞性肺疾病的系统评价和荟萃分析。
Ann Am Thorac Soc. 2020 Oct;17(10):1308-1318. doi: 10.1513/AnnalsATS.202001-023OC.
7
Symptomatic burden of COPD for patients receiving dual or triple therapy.接受双联或三联疗法的慢性阻塞性肺疾病患者的症状负担
Int J Chron Obstruct Pulmon Dis. 2018 Apr 27;13:1365-1376. doi: 10.2147/COPD.S163717. eCollection 2018.
8
Cost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenarios.慢性阻塞性肺疾病的成本效益模型：假设治疗方案的跨模型比较。
Value Health. 2014 Jul;17(5):525-36. doi: 10.1016/j.jval.2014.03.1721. Epub 2014 May 14.
9
Total and state-specific medical and absenteeism costs of COPD among adults aged ≥ 18 years in the United States for 2010 and projections through 2020.2010 年美国≥18 岁成年人 COPD 的总医疗费用和各州具体医疗费用及旷工费用，以及到 2020 年的预测。
Chest. 2015 Jan;147(1):31-45. doi: 10.1378/chest.14-0972.
10
A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease.用于慢性阻塞性肺疾病经济评估的终生马尔可夫模型。
Pharmacoeconomics. 2012 Sep 1;30(9):825-40. doi: 10.2165/11591340-000000000-00000.
Zotero 插件